pulmicort and Fever

Systemic corticosteroid is currently the standard adjunctive therapy for tuberculous pyrexia. A preliminary prospective open study to examine the efficacy of inhaled budesonide at a dose of 2,400 micrograms daily in the management of this condition was performed. Out of nine non-HIV infected patients with tuberculous pyrexia studied, four patients succeeded to achieve defervescence at a mean of 3.25 days (range = 2 to 5 days), while the rest of the patients failed to do so within 7 days. None of the patients had unwanted side effects of systemic corticosteroid and patients' acceptance of such therapy was high. The potential usefulness of inhaled corticosteroid in some patients with tuberculous pyrexia might warrant further evaluation.

Topics: Administration, Inhalation; Adolescent; Adult; Budesonide; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Fever; Humans; Male; Middle Aged; Treatment Outcome; Tuberculosis, Pulmonary

This case report describes a rare situation in which a superinfected cyst of the urachus complicated initially unknown and inactive Crohn's disease.. A 21-year-old man presented a chronic fever finally attributed to a superinfected urachal cyst. Six months after ablation of the cyst, progressive Crohn's disease was diagnosed.. The association of Crohn's disease and a superinfected urachal cyst is extremely rare. The case reported here is original in two aspects: the slowly progressive Crohn's disease was diagnosed after its complication; the superinfection developed through local bacterial translocation (ileal loop adjacent to the urachal cyst).

Topics: Adult; Anti-Inflammatory Agents; Budesonide; Chronic Disease; Crohn Disease; Disease Progression; Fever; Humans; Male; Time Factors; Tomography, X-Ray Computed; Urachal Cyst

Topics: Administration, Inhalation; Administration, Topical; Anti-Inflammatory Agents; Budesonide; Fever; Glucocorticoids; Humans; Nebulizers and Vaporizers; Powders; Treatment Outcome; Tuberculosis